ESC CONGRESS 2014

30 August - 03 September 2014, Barcelona - Spain

Session Details

Meet the Trialist IV: ODYSSEY COMBO II - ODYSSEY FH I and FH II - ODYSSEY LONG TERM
Mon 01 Sep 15:40 - 16:24 Cardiovascular prevention: interventions and outcomes Meet the Trialists Barcelona - Central Village
Chairpersons: Thomas Felix LUSCHER (Zurich, CH)

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
15:404014Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study.Christopher Paul CANNON (Boston, US)
15:544015Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies.Michel FARNIER (Dijon, FR)
16:10 Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients.